Forum Topic Genetics
  • Conversation: How Low Can the Price of a Next Generation DNA Sequencer Go?

    • April 17, 2018 10:39 AM BST
    • How Low Can the Price of a Next Generation DNA Sequencer Go?

      The next generation of DNA sequencers has arrived, and with it, a clash of titans: Illumina, Thermo Fisher and Qiagen are all competing for the clinical diagnostics market.
      Next-generation sequencing (NGS) companies are redefining DNA sequencing. What began as small-scale PCR and Sanger sequencing efforts have now mushroomed into a $20Bn market with broad medical implications for cancer and chronic disease, including FDA-approved tests for cystic fibrosis and large-scale cancer genome studies that have led to new targeted therapies.
      Illumina controls 75% of this market with its sequencing-by-synthesis (SBS) method. Its closest competitor is Thermo Fisher, which rides on ion semiconductor sequencing (Ion Torrent), followed by Pacific Biosciences’ single molecule real-time (SMRT) sequencing. Together, Thermo Fisher and Pacific Life Sciences control the remaining 25% of the market.
      Read more: https://labiotech.eu/ngs-dna-sequencing-illumina-qiagen/

Add Reputation

Do you want to add reputation for this member by this post?

or cancel
​